Antifungal drugs
Journal of Current Hematology & Oncology Research · 2023
DOI: 10.51271/jchor-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, 2023. Verfasst von İlknur Akkuş und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978. The discovery of first-generation azoles (fluconazole and itraconazole) in the 1990s has created a new step in the treatment of fungi. In the years that followed, with the development of lipid formulations of amphotericin B, the introduction of second-generation azoles, and the release of the most recently developed class, echinocandins, the foundations of today’s existing antifungal classes were laid. This article is aimed to review the mechanism of action, side effects and clinical use indications of the main antifungal drugs used in the treatment of systemic fungal infections.
Zitieren
APA
Akkuş, İ., & Kaçmaz, B. (2023). Antifungal drugs. Journal of Current Hematology & Oncology Research. https://doi.org/10.51271/jchor-0010
Vancouver
Akkuş İ, Kaçmaz B. Antifungal drugs. Journal of Current Hematology & Oncology Research. 2023. doi:10.51271/jchor-0010
BibTeX
@article{Akku2023,
author = {Akkuş, İlknur and Kaçmaz, Birgül},
title = {Antifungal drugs},
journal = {Journal of Current Hematology & Oncology Research},
year = {2023},
doi = {10.51271/jchor-0010}
}
EUVIMED